News
New drug application accepted by FDA for GSK’s momelotinib
Therapy for the treatment of myelofibrosis has received significant results from recent trials, GSK has announced that the US FDA has accepted the new drug application for momelotinib.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Therapy for the treatment of myelofibrosis has received significant results from recent trials, GSK has announced that the US FDA has accepted the new drug application for momelotinib.